A recently developed preparation of C1 inhibitor concentrate was evaluated in patients with hereditary angioedema in two trials. In the acute-attack treatment trial, the time to relief of an acute attack of angioedema was significantly shorter with the C1 inhibitor than with placebo. In the prophylaxis trial, the attack rate over a 12-week period was significantly lower with the C1 inhibitor than with placebo.

In a randomized trial, 72 patients with hereditary angioedema presenting with acute attacks of angioedema were randomly assigned to receive either ecallantide, a recombinant plasma kallikrein inhibitor, or placebo. The median treatment outcome score, a composite patient-reported outcome measure, was significantly better at 4 hours in the ecallantide group than in the placebo group.

Two randomized trials evaluated the effect of the bradykinin-receptor antagonist icatibant in patients with hereditary angioedema presenting with acute attacks. The primary end point in each trial was the median time to clinically significant relief of symptoms. In one trial, the primary end point was reached significantly faster with icatibant than with tranexamic acid. In the other trial, the primary end point was not reached significantly faster with icatibant than with placebo.

In this large observational study based on data collected as part of clinical care in the United Kingdom, antiepileptic-drug treatment was not associated with an increased risk of suicide-related events among patients with epilepsy, but the use of these drugs was associated with suicide-related events in patients with depression.

This study shows that myocardial fibrosis is an early characteristic of hypertrophic cardiomyopathy caused by sarcomere mutations. The C-terminal propeptide of procollagen type I was shown to be a serum biomarker of early myocardial fibrosis.